2116-2117 / 2351
Pembrolizumab
Anti-PD-1
Total
N=117
HPV+
N=34
HPV-
N=81
ORR
24.8%
20.6%
27.2%
MEDI4736
Anti-PD-L1
Total
N=62
PD-L1+
N=22
PD-L1-
N=37
ORR
11%
18%
8%
Seiwert et al, ASCO 2015
|
|
2116-2117 / 2351
Pembrolizumab
Anti-PD-1
Total
N=117
HPV+
N=34
HPV-
N=81
ORR
24.8%
20.6%
27.2%
MEDI4736
Anti-PD-L1
Total
N=62
PD-L1+
N=22
PD-L1-
N=37
ORR
11%
18%
8%
Seiwert et al, ASCO 2015